南宁；；你；；_老虎社区_美港股上老虎 - 老虎社区

1
评论
收藏

赢颖
09-24

南宁；；你；；

劲方医药涨超11%公司研究数据亮相AACR年会目前已形成RAS靶向疗法矩阵

劲方医药-B(02595)股价涨超11%，截至发稿涨10.67%，报43.78港元。此前在美国癌症研究协会(AACR)年会上，劲方医药三款大、小分子产品(GFH276、GFS202A、GFH375)临床前研究入选年会壁报环节，研发进度领先，靶向多个大适应症，展现其管线创新与丰富。国投证券指出，劲方医药为全球布局的创新药企，聚焦肿瘤、免疫疾病领域，已形成RAS靶向疗法矩阵，并积极拓展其他“全球新”靶向药及新疗法管线，已布局KRAS G12C、KRAS G12D等多个靶点分子，其中核心产品KRAS G12D抑制剂GFH375已在胰腺癌、NSCLC等领域取得积极数据，后续临床进展值得关注。

劲方医药涨超11%公司研究数据亮相AACR年会目前已形成RAS靶向疗法矩阵

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

1

举报

评论

推荐
最新

empty

暂无评论

热议股票

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":481945033327344,"tweetId":"481945033327344","gmtCreate":1758686471910,"gmtModify":1758686474118,"author":{"id":4211411675720482,"idStr":"4211411675720482","authorId":4211411675720482,"authorIdStr":"4211411675720482","name":"赢颖","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":6,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":0,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"html":"<html><head></head><body><p>南宁；；你；；</p></body></html>","htmlText":"<html><head></head><body><p>南宁；；你；；</p></body></html>","text":"南宁；；你；；","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/481945033327344","repostId":2569290427,"repostType":2,"repost":{"id":"2569290427","kind":"news","pubTimestamp":1758682860,"share":"https://www.laohu8.com/m/news/2569290427?lang=&edition=full","pubTime":"2025-09-24 11:01","market":"hk","language":"zh","title":"劲方医药涨超11%公司研究数据亮相AACR年会目前已形成RAS靶向疗法矩阵","url":"https://stock-news.laohu8.com/highlight/detail?id=2569290427","media":"动脉网","summary":"劲方医药-B(02595)股价涨超11%，截至发稿涨10.67%，报43.78港元。此前在美国癌症研究协会(AACR)年会上，劲方医药三款大、小分子产品(GFH276、GFS202A、GFH375)临床前研究入选年会壁报环节，研发进度领先，靶向多个大适应症，展现其管线创新与丰富。国投证券指出，劲方医药为全球布局的创新药企，聚焦肿瘤、免疫疾病领域，已形成RAS靶向疗法矩阵，并积极拓展其他“全球新”靶向药及新疗法管线，已布局KRAS G12C、KRAS G12D等多个靶点分子，其中核心产品KRAS G12D抑制剂GFH375已在胰腺癌、NSCLC等领域取得积极数据，后续临床进展值得关注。","content":"<html><body><article><p><a href=\"https://laohu8.com/S/02595\">劲方医药-B</a>(02595)股价涨超11%，截至发稿涨10.67%，报43.78港元。此前在美国癌症研究协会(AACR)年会上，劲方医药三款大、小分子产品(GFH276、GFS202A、GFH375)临床前研究入选年会壁报环节，研发进度领先，靶向多个大适应症，展现其管线创新与丰富。国投证券指出，劲方医药为全球布局的创新药企，聚焦肿瘤、免疫疾病领域，已形成RAS靶向疗法<a href=\"https://laohu8.com/S/301365\">矩阵</a>，并积极拓展其他“全球新”靶向药及新疗法管线，已布局KRAS G12C、KRAS G12D等多个靶点分子，其中核心产品KRAS G12D抑制剂GFH375已在胰腺癌、NSCLC等领域取得积极数据，后续临床进展值得关注。</p></article></body></html>","source":"tencent","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>劲方医药涨超11%公司研究数据亮相AACR年会目前已形成RAS靶向疗法矩阵</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n劲方医药涨超11%公司研究数据亮相AACR年会目前已形成RAS靶向疗法矩阵\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-09-24 11:01 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025092411261295417f29&s=b><strong>动脉网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>劲方医药-B(02595)股价涨超11%，截至发稿涨10.67%，报43.78港元。此前在美国癌症研究协会(AACR)年会上，劲方医药三款大、小分子产品(GFH276、GFS202A、GFH375)临床前研究入选年会壁报环节，研发进度领先，靶向多个大适应症，展现其管线创新与丰富。国投证券指出，劲方医药为全球布局的创新药企，聚焦肿瘤、免疫疾病领域，已形成RAS靶向疗法矩阵，并积极拓展其他“全球新”...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025092411261295417f29&s=b\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK1161":"生物科技","BK1574":"生物医药B类股","02595":"劲方医药-B","09939":"开拓药业-B","BK1515":"抗疫概念"},"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025092411261295417f29&s=b","is_english":false,"share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","article_id":"2569290427","content_text":"劲方医药-B(02595)股价涨超11%，截至发稿涨10.67%，报43.78港元。此前在美国癌症研究协会(AACR)年会上，劲方医药三款大、小分子产品(GFH276、GFS202A、GFH375)临床前研究入选年会壁报环节，研发进度领先，靶向多个大适应症，展现其管线创新与丰富。国投证券指出，劲方医药为全球布局的创新药企，聚焦肿瘤、免疫疾病领域，已形成RAS靶向疗法矩阵，并积极拓展其他“全球新”靶向药及新疗法管线，已布局KRAS G12C、KRAS G12D等多个靶点分子，其中核心产品KRAS G12D抑制剂GFH375已在胰腺癌、NSCLC等领域取得积极数据，后续临床进展值得关注。","news_type":1,"symbols_score_info":{"02595":0.9,"09939":1.5}},"isVote":1,"tweetType":1,"viewCount":193,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":10,"optionInvolvedFlag":false,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}